Stock, pipeline and biotech catalyst intelligence
Clinical portfolio
| Asset | Indication | Stage | Milestone | Signals ? |
|---|---|---|---|---|
| FB102 | Celiac Disease | Phase 2 | Dec 31, 2026 | Big moverMgmt interest |
| FB102 (Anti-CD122 Antibody) | Alopecia Areata | Phase 1b | Dec 31, 2026 | — |
| FB102 | Graft-versus-host disease | Phase 1 | Dec 31, 2026 | — |
Upcoming milestones
Company profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
Celiac Disease
Data readoutAlopecia Areata
Data readout